Request and Response Register

Freedom of Information Request Reference: 11061

Date Received: 16/01/2026

Summary:
Question 1. How many patients have a current diagnosis for Spinal Muscular Atrophy (ICD-10 Code G12.0, G12.1, G12.8 and G12.9) at your trust? Question 2. How many patients have been treated in the last 4 months (September to December 2025) with the following products: • Evrysdi (Risdiplam) - total patients • Spinraza (Nusinersen) - total patients • Zolgensma (Onasemnogene) - total patients • Evrysdi (Risdiplam) – new* patients • Spinraza (Nusinersen) – new* patients • Zolgensma (Onasemnogene) – new* patients

Date of Response: 13/02/2026
View Response: 11061.pdf

Freedom of Information Request Reference: 11059

Date Received: 16/01/2026

Summary:
Please can you inform me if your Health Board is currently or intends to work with the private company Flatiron Health UK in the future. If you are can you detail the length of the contract and the extent to which patient data including CHIs are being sent to this company.

Date of Response: 11/02/2026
View Response: 11059.pdf

Freedom of Information Request Reference: 11058

Date Received: 15/01/2026

Summary:
Can you please provide the Current Market Rent for GP surgeries within the Edinburgh city boundary for the last 24 months." is possible I would like the following surgeries annual rent and £X per square meter if possible • Blackhall Edinburgh • Murrayfield medical practice Edinburgh • Stockbridge heath centre Edinburgh • Leven medical practice • Gilmore medical practice

Date of Response: 12/02/2026
View Response: 11058.pdf

Freedom of Information Request Reference: 11057

Date Received: 15/01/2026

Summary:
1) How many international hires, with a breakdown by country and job role (junior doctor, nurse etc.) have been recruited from 'red list' countries during each of the following financial years: - o 2019/20 o 2020/21 o 2021/22 o 2022/23 o 2023/24 o 2024/25 o 2025/26 (most recent) 2) How many international hires from 'red list' countries are still employed by your health board, again broken down by country and job role?

Date of Response: 11/02/2026
View Response: 11057.pdf

Freedom of Information Request Reference: 11056

Date Received: 16/01/2026

Summary:
NHS WAITING TIMES 1)For the year 2025, pls outline how many patients who were on waiting lists, had their 'clocks' reset. 2) Out of the total, pls specify the reasons for the clocks being reset ie how many were Did Not Attend and how many were Could Not Attend. 3) Pls also outline how many patients were removed from a waiting list altogether and what the clinical reason was for their removal. For the above three questions pls provide answers for the years, 2021, 2022, 2023 and 2024 as well.

Date of Response: 13/02/2026
View Response: 11056.pdf

Freedom of Information Request Reference: 11054

Date Received: 15/01/2026

Summary:
To ask how many patients have been admitted to hospital in your area following assault by a sharp object in the following years... 2025 2024 2023 2022 2021 Could this information be broken down by year.

Date of Response: 12/02/2026
View Response: 11054.pdf

Freedom of Information Request Reference: 11053

Date Received: 15/01/2026

Summary:
I am writing to request recorded information under the Freedom of Information (Scotland) Act 2002 relating to work-related asthma potentially linked to salmon or seafood processing. I appreciate that “salmon processing” may not exist as a discrete category. Where it does not, please use the closest available proxy such as fish processing or seafood processing recorded as an occupation or industry, and any available exposure notes. Time period Please cover calendar years 2015 to 2025 inclusive. 1. Work-related asthma counts Please provide annual anonymised counts of patients where occupational asthma or work-related asthma is recorded (or the closest equivalent code/flag used by the Board), and where occupation or industry is recorded as fish processing, seafood processing, or salmon processing (or closest available). If held, please provide the counts split by: a) year b) the patient’s NHS Board area (if different to this Board) or by locality within the Board if that is how it is recorded. 2. Recorded trigger or suspected agent If your systems record suspected trigger or causative agent for asthma, please provide annual anonymised counts where the trigger/agent is recorded as fish or seafood proteins, fish processing, seafood aerosols, or similar terms used locally. 3. Clinic pathway signal If held, please provide annual counts of referrals to respiratory clinics or occupational medicine services where the referral is flagged as work-related asthma or occupational asthma and the occupation/industry is fish or seafood processing (as above). 4. Recording practice Please confirm whether your systems include standard fields for: a) occupation or industry, and b) suspected occupational trigger or causative agent, for asthma referrals or respiratory clinic episodes, and if so what categories are available that relate to fish or seafood processing.

Date of Response: 10/02/2026
View Response: 11053.pdf

Freedom of Information Request Reference: 11051

Date Received: 15/01/2026

Summary:
Please advise what national or international guideline were used by the Chalmers Gender Identity Service to produce prescribing guidance for GPs e.g. shared care agreements, directed/ local enhanced services or prescribing guidelines. This includes advice given to GPs on prescribing oestrogen or testosterone (drug preparations and dose titration), blood monitoring and monitoring for adverse effects.

Date of Response: 12/02/2026
View Response: 11051.pdf

Freedom of Information Request Reference: 11050

Date Received: 14/01/2026

Summary:
The amount of births overall in NHS Lothian in 2025 The amount of homebirths completed at home in NHS Lothian in 2025

Date of Response: 10/02/2026
View Response: 11050.pdf

Freedom of Information Request Reference: 11047

Date Received: 14/01/2026

Summary:
1. The total number of NHS dental patients registered with a NHS dentist under the board. 2. The total number of patients believed to living under the board but not registered with an NHS dental practice. 3. The number of NHS dental patients who have not had a dental appointment in the last (i) 12 months (ii) 24 months (iii) 36 months (iiii) 48 months (iiii) 5 Years or more For each figure above, please, if possible, reveal what they are in terms of the % of the overall amount of patients under the board. So for example state how many patients haven't had an appointment in 12 months and how many people that is within the overall number of patients under the board.

Date of Response: 11/02/2026
View Response: 11047.pdf

Freedom of Information Request Reference: 11046

Date Received: 14/01/2026

Summary:
1. Confirmation of whether or not board receives an annual report of sorts regarding NHS dentistry. In other words, a report or body of analysis that provides an overview of a year in terms of dental treatment, patient dental health and figures regarding treatment. 2. If so please provide a copy of that annual report/analysis for the last five years. Please note I am referring to document/briefing material which informs the board about the specific details of dental treatment of the board, such as how many patients were treated, emerging trends, potential issues etc. 3. Please provide the latest document or analysis specifically regarding tooth decay.

Date of Response: 11/02/2026
View Response: 11046.pdf

Freedom of Information Request Reference: 11045

Date Received: 14/01/2026

Summary:
Q1. How many patients were treated by the rheumatology department in the past 3 months with the following: •Tocilizumab – for any disease •Tocilizumab for rheumatoid arthritis (RA) only •Tocilizumab for giant cell arteritis (GCA) only Q2. How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab? Q3. How many patients were treated in A&E in the past 3 months for giant cell arteritis (GCA) with Tocilizumab? Q4. In the past 3 months, how many patients with a primary diagnosis of GCA (ICD10 codes M31.5 or M31.6) were: •Admitted as an inpatient •Treated in A&E

Date of Response: 10/02/2026
View Response: 11045.pdf

Freedom of Information Request Reference: 11044

Date Received: 14/01/2026

Summary:
1. A list of all reasons recognised by the health board for a dental patient to become deregistered. 2. The number of dental Patients who are recognised as having been deregistered as NHS patients in the last seven years (2019, 2020, 2021, 2022, 2023, 2024 and 2025) Please provide a breakdown of the number of deregistered patients per year and by reason for deregistration.

Date of Response: 09/02/2026
View Response: 11044.pdf

Freedom of Information Request Reference: 11043

Date Received: 14/01/2026

Summary:
FOI Request: Acute Myeloid Leukaemia (AML) Patients 1. How many patients have been diagnosed with Acute Myeloid Leukaemia (AML) at your Trust in the last 12 months a. Of these patients how many are refractory/relapsed (R/R)? b. How many of the R/R patients were FLT3 positive? 2. How many patients have been treated for AML in the latest 12 months with the following treatments • Venetoclax with azacitidine • Midostaurin • Quizartinib • Gemtuzumab • Ivosidenib with azacitidine • Liposomal cytarabine–daunorubicin • Oral azacitidine • Gilteritinib • Palliative care • Enrolled in a clinical trial 3. How many relapsed/refractory patients have been treated for AML in the last 12 months with the following treatments (This question relates to treatments administered to relapsed/refractory AML patients in clinical practice, regardless of licence status or funding route (including any off-label use). • Venetoclax with azacitidine • Midostaurin • Quizartinib • Gemtuzumab • Ivosidenib with azacitidine • Liposomal cytarabine–daunorubicin • Oral azacitidine • Gilteritinib • Palliative care • Enrolled in a clinical trial 4. Of your AML patient how many were tested as below in the last 12 months • Received an FLT3 mutation test when they were diagnosed • Received an FLT3 mutation test when their disease relapsed • Received an FLT3 mutation test when their disease became refractory

Date of Response: 11/02/2026
View Response: 11043.pdf

Freedom of Information Request Reference: 11042

Date Received: 13/01/2026

Summary:
For each of the last five completed financial years for which information is held, please provide: 1. The total annual sums paid by or attributable to this NHS health board in respect of maternity/obstetric clinical negligence claims, including: o Compensation or damages paid to pursuers o Defender legal costs paid by or on behalf of the Board 2. The number of maternity/obstetric clinical negligence claims: o Newly intimated during each financial year o Settled during each financial year (whether with or without admission of liability) 3. Where applicable, confirmation of whether claims or payments are: o Recorded locally by this NHS health board, or o Managed centrally (for example by the Central Legal Office), but with figures attributable to the Board.

Date of Response: 06/02/2026
View Response: 11042.pdf

Freedom of Information Request Reference: 11041

Date Received: 14/01/2026

Summary:
1. How many students applied to the Nursing and Midwifery return to practice course from your health board area for the following academic years: 2018, 2019, 2020, 2021, 2022, 2023, 2024 2. How many students met the minimum specified qualifications within application for the Nursing and Midwifery return to practice course from your health board area for the following academic years: 2018, 2019, 2020, 2021, 2022, 2023, 2024 3. The average, mean, and most number of attempts required by individuals to receive a place on the Nursing and Midwifery return to practice course from your health board area for the following academic years: 2018, 2019, 2020, 2021, 2022, 2023, 2024

Date of Response: 11/02/2026
View Response: 11041.pdf

Freedom of Information Request Reference: 11039

Date Received: 14/01/2026

Summary:
I would be grateful if you could instead provide all information and documentation held by NHS Lothian showing or tending to show: 1. The average waiting time for a patient to be seen by NHS Lothian’s Ophthalmology Department, following a routine referral from any referrer. 2. The average waiting time for a patient to be seen by NHS Lothian’s Ophthalmology Department, following a routine referral from a referrer who was not a GP in December 2020.

Date of Response: 11/02/2026
View Response: 11039.pdf

Freedom of Information Request Reference: 11038

Date Received: 14/01/2026

Summary:
In the last 3 months (October, November, December 2025), how many haemophilia A and B and von Willebrand patients were treated with the following coagulation factors in your trust and how much volume (IUs or mg) was used? Hemlibra (non-inhibitor patients) Hemgenix Altuvoct Advate Adynovi Elocta Esperoct NovoEight ReFacto AF Nuwiq Hympavzi Idelvion Refixia Alprolix BeneFIX Replenine Rixubis Veyvondi Voncento Wilate Willfact

Date of Response: 11/02/2026
View Response: 11038.pdf

Freedom of Information Request Reference: 11037

Date Received: 12/01/2026

Summary:
Q1. How many patients who have a current diagnosis of Multiple Sclerosis received treatment in the last six months with any of the following treatment regimens (July 2025 – December 2025)? • Ocrevus (ocrelizumab) IV (300mg/30ml) • Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml) • Kesimpta (ofatumumab) • Briumvi (ublituximab) • Mavenclad (cladribine) • Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) • Natalizumab (Tysabri and Tyruko) Q1a. Of the patients identified in question one, how many patients received the same treatment in the previous six-month period? (i.e. How many of the same patients received treatment with each treatment regimen in January 2025 to June 2025 AND July 2025 – December 2025?) • Ocrevus (ocrelizumab) IV (300mg/30ml) • Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml) • Kesimpta (ofatumumab) • Briumvi (ublituximab) • Mavenclad (cladribine) • Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) • Natalizumab (Tysabri and Tyruko) Q2. How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (July 2025 – December 2025)? Q2a. Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis? • Ocrevus (ocrelizumab) IV (300mg/30ml) • Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml) • Kesimpta (ofatumumab) • Briumvi (ublituximab) • Mavenclad (cladribine) • Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) • Natalizumab (Tysabri and Tyruko)

Date of Response: 06/02/2026
View Response: 11037.pdf

Freedom of Information Request Reference: 11036

Date Received: 13/01/2026

Summary:
Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)? Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months? Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments: • R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) • R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) • Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) • R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) • R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) • R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) • (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) • R-GemOX (rituximab, gemcitabine and oxaliplatin) • Axicabtagene ciloleucel • Tisagenlecleucel • Epcoritamab • Loncastuximab tesirine • Glofitamab • Any other SACT • Stem cell transplant or bone marrow transplant (autologous or allogeneic) Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL): • Axicabtagene ciloleucel (Yescarta) • Tisagenlecleucel • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) • R-GemOX (rituximab, gemcitabine and oxaliplatin) • Stem cell transplant or bone marrow transplant (autologous or allogeneic) • Glofitamab • Any other treatments Q4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL)? Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments: • CAR-T Therapy (E.g. Axicabtagene ciloleucel) • Stem cell transplant or bone marrow transplant (autologous or allogeneic) • Any other treatment

Date of Response: 10/02/2026
View Response: 11036.pdf

Freedom of Information Request Reference: 11035

Date Received: 13/01/2026

Summary:
Can you please advise the average waiting time for a person for a MRI back scan when the person has been referred for the scan from the "NHS Lothian Department of Spinal iMSK Advanced Practice" (from referral date to the date of the appointment for the MRI scan)? This would be for a person is on the normal waiting list and not the urgent waiting list for a MRI back scan.

Date of Response: 10/02/2026
View Response: 11035.pdf

Freedom of Information Request Reference: 11034

Date Received: 13/01/2026

Summary:
AI system information 1. How many artificial intelligence (AI) systems does your trust/health board currently have in development and what is the name of the AI system? 2. How many AI systems are currently deployed within your trust/health board and what is the name of the AI system? 3. For every AI model currently being used or developed in your trust: 3a. Is the AI model being used operationally, clinically, or for another purpose? 3b. What department(s) is the AI system being used in? 3c. What month and year was the AI system first deployed? (n/a if in development). 3d. Was the AI system created by a commercial entity, university, in-house, or within another NHS trust? Please give the name of the organisation. 3e. What is the AI systems architecture? (e.g. deep neural network, random forest, logistic regression, large language model). 3f. Which coding language and packages are used to deploy the AI system? (e.g. python - scikit-learn, pytorch, tensorflow) 3g. What is the nature of the input of the AI system? (e.g. a medical scan, free text notes, tables of lab results). 3h. What is the nature of the output of the AI system? (e.g. a masked image, a risk score, natural text). 3i. How was the AI system validated in the target population before deployment? 3j. What measures are in place to monitor for degradation in the performance of the AI system post-deployment? 3k. What was the cost to procure the AI model and what is the ongoing cost of use? 3l. Which departmental budget is the cost paid from? Data management 4. Was any local patient data used for training or fine tuning the AI system? 5. Is any patient data collected specifically for the purpose of training any of the AI systems currently in development or deployment? 6. Do you share, or plan to share, any patient data with third-party developers for AI-related purposes? If yes, please provide details of the data-sharing agreement or relevant policy. Regulation 7. What is the regulation and certification of the AI model under the European Union Medical Device Directive and/or United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA)? Patient/public involvement 8. Was any patient/public engagement undertaken before deployment of the AI system? 9. Is there any ongoing patient/public engagement input into the use of AI within your organisation? Governance 10. Who has responsibility for the AI systems being using? 11. Does your organisation have a governance policy that covers: 11a. Use of AI systems within your organisation? 11b. Ongoing evaluation of an AI model's performance after deployment? 11c. How to monitor for bias in the AI system and how to mitigate against this?

Date of Response: 13/02/2026
View Response: 11034.pdf

Freedom of Information Request Reference: 11033

Date Received: 12/01/2026

Summary:
If NHS Lothian will be reinstating and expanding their contract with GJH for knee surgery?

Date of Response: 09/02/2026
View Response: 11033.pdf

Freedom of Information Request Reference: 11032

Date Received: 13/01/2026

Summary:
As a research project for a cyber EPQ, I am seeking information relating to Business continuity plans (BCPs). 1. Does NHS Lothian have a BCP? 2. When was it last updated? 3. Does it include cyber-specific scenarios? 4. Have you conducted any cyber incident exercises? 5. Are the documented BCPs updated after major incidents, is there a lessons learnt process?

Date of Response: 10/02/2026
View Response: 11032.pdf

Freedom of Information Request Reference: 11031

Date Received: 13/01/2026

Summary:
Question 1. How many patients with HIV in total were seen for care and treated with ART in your Trust in the latest 3 months of available data? ______ total patients treated with ART Question 2. How many patients newly diagnosed with HIV were initiated on Antiretroviral Therapy (ART) in your Trust in the latest 3 months of available data? _____ total patients newly diagnosed initiated on ART Question 3. How many patients with HIV have had their ART switched in your Trust in the latest 3 months of available data? _____ patients who switched therapy Question 4. Of the patients identified in Question 3, how many were switched from/to the following therapies? Emtricitabine/tenofovir alafenamide (fixed dose combination) + any other ART to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Emtricitabine/tenofovir alafenamide (fixed dose combination) + any other ART to Dovato (dolutegravir/lamivudine) Emtricitabine/tenofovir disoproxil (fixed dose combination) + any other ART to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Emtricitabine/tenofovir disoproxil (fixed dose combination) + any other ART to Dovato (dolutegravir/lamivudine) Triumeq (dolutegravir/abacavir/lamivudine) to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Triumeq (dolutegravir/abacavir/lamivudine) to Dovato (dolutegravir/lamivudine) Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) to Dovato (dolutegravir/lamivudine) Any other ART** to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Any other ART** to Dovato (dolutegravir/lamivudine) Question 5. Please specify the dates of the latest 3 months of available date in month / year format.

Date of Response: 10/02/2026
View Response: 11031.pdf

Freedom of Information Request Reference: 11030

Date Received: 12/01/2026

Summary:
MENTAL HEALTH — CAHHS REFERRALS AND WAITS For the year, 2025: 1) Pls outline the median wait (in days) between the initial meeting (assessment/choice appointment), where a CAMHS professional will talk to a patient and decide on how to help them to the start of treatment. 2) Pls also outline the longest wait (in days) between the initial meeting (assessment/choice appointment) and the start of treatment. 3) Pls supply the above answers for the years, 2023 and 2024. Also: 4) As of January 12, 2026, please outline the number of vacancies in your health board in the following positions: 1. Psychologist 2. Neuropsychologist 3. consultant psychiatrist 4. Psychotherapist 5. Education Mental Health Practitioners (EMHPs) 6. Children's Wellbeing Practitioners (CWPs)

Date of Response: 12/02/2026
View Response: 11030.pdf

Freedom of Information Request Reference: 11028

Date Received: 12/01/2026

Summary:
1. How many people were removed from an outpatient/inpatient waiting list in the calendar year 2025 for a reason other than having had the appointment, or death. Please provide the reasons for this removal in each case. For example, X were removed due to leaving the area. 2. Whether it is the case that people are removed from waiting lists if they do not confirm their intention to remain on it within 21 days in response to a letter sent to them checking this. If this is the case, how many were removed for this reason in 2025?

Date of Response: 09/02/2026
View Response: 11028.pdf

Freedom of Information Request Reference: 11027

Date Received: 09/01/2026

Summary:
• The number of incidents of bullying and harassment (excluding sexual misconduct) reported each year for the last five years • A breakdown of incidents of bullying and harassment by medical specialty including anaesthetists • The number of incidents of sexual misconduct reported each year for the last five years. • A breakdown of incidents of sexual misconduct by medical specialty including anaesthetists • The number of staff dismissed as a result of each of these incidents.

Date of Response: 06/02/2026
View Response: 11027.pdf

Freedom of Information Request Reference: 11026

Date Received: 09/01/2026

Summary:
• How many doctors are on a SAS contract, broken down by medical specialty? • How many are doctors are on specialist doctor contracts, broken down by medical specialty? • How many doctors are on specialty doctor contracts, broken down by medical specialty? • How many doctors are on associate specialists, broken down by medical specialty? • How many doctors are on a staff grade contract, broken down by medical specialty? • How many doctors are employed in the Trust that are not in a formal training programme or on a SAS or consultant contract, broken down by medical specialty?

Date of Response: 02/02/2026
View Response: 11026.pdf

Freedom of Information Request Reference: 11025

Date Received: 12/01/2026

Summary:
Please could you provide the following details regarding your Trust’s use of digital systems in the endoscopy, respiratory and urology department: 1. Does your Trust currently use any software systems to manage clinical records, diagnostics, or workflows within endoscopy, cytoscopy and bronchoscopy? 2. If yes, please provide: o The name of the software provider and product. o The start date and duration of the current contract. o The expiry date or next renewal date of the contract. o Whether the contract includes options for extension or renewal.

Date of Response: 10/02/2026
View Response: 11025.pdf

Freedom of Information Request Reference: 11024

Date Received: 09/01/2026

Summary:
Can a patient's assessment for a neurodevelopmental condition be expedited for an assessment if there is a serious comorbid mental health illness/issue and what would be the process within NHS Lothian specifically in the west Lothian area for this to be expedited.

Date of Response: 03/02/2026
View Response: 11024.pdf

Freedom of Information Request Reference: 11023

Date Received: 12/01/2026

Summary:
From 1st October 2025 to 31st December please provide a breakdown of: • Total trust spend with framework agencies for locum AHP/HSS staffing. Please provide a further breakdown for locum AHP/HSS staffing by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st October 2025 to 31st December please provide a breakdown of: • Total trust spend with off-framework agencies for locum AHP/HSS staffing. Please provide a further breakdown for locum AHP/HSS staffing by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st October 2025 to 31st December please provide a breakdown of: • Total trust spend with the internal trust bank or associated external provider for locum AHP/HSS staffing Please provide a further breakdown for locum AHP/HSS staffing by: • Spend per grade • Spend per specialty • Spend per internal or associated external provider Please confirm your allocated budget for agency locum AHP/HSS staffing for the period 1st October 2025 to 31st December Please confirm the framework you utilise for AHP/HSS agency staff.

Date of Response: 06/02/2026
View Response: 11023.pdf

Freedom of Information Request Reference: 11021

Date Received: 12/01/2026

Summary:
1. Whether cold debriefs are routinely conducted following critical events 2. The specified timeframe for when cold debriefs are held following an event 3. Which staff groups or roles are expected or required to attend cold debriefs, including nonparticipants of the critical event 4. Which role, team, or department is responsible for organising and facilitating cold debriefs 5. Whether a standard pro forma, template, or guidance document is used for cold debriefs, and if so, a copy of the most recent version.

Date of Response: 09/02/2026
View Response: 11021.pdf

Freedom of Information Request Reference: 11019

Date Received: 09/01/2026

Summary:
1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from September to December 2025: • Aflibercept • Bevacizumab • Brolucizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - Lucentis • Ranibizumab - Biosimilar 2. Please provide the number of injections/implants administered within the four-month period from September to December 2025 with the below treatments for noninfectious Uveitis (NIU) only • Dexamethasone • Fluocinolone acetonide

Date of Response: 30/01/2026
View Response: 11019.pdf

Freedom of Information Request Reference: 11017

Date Received: 08/01/2026

Summary:
Please could I request the following information: • Agency locum spend between August 2025 to present • Breakdown of speciality and grade this spend was used in • The breakdown between direct engagement and non direct engagement this spend was used in • If any non direct engagement spend, what speciality and grade was this used in • Any off framework spend? If so please include speciality and grade. • A list of all service or general managers at the trust including the department they cover

Date of Response: 05/02/2026
View Response: 11017.pdf

Freedom of Information Request Reference: 11016

Date Received: 08/01/2026

Summary:
From January 2025 to 31st December 2025 please provide a breakdown month by month of total trust spend for framework agency staff within NON medical NON clinical, please break it down by: • Total spend • Spend per area EG – Admin and Clerical: Includes roles like receptionists, medical secretaries, ward clerks, administrators, and HR staff. Estates and Facilities: Encompasses porters, cleaners, caterers, maintenance workers, security staff, and drivers. Scientific, Therapeutic, and Technical Staff: A diverse group including various professions that do not fall under the direct 'medical' or 'nursing' umbrella. Corporate Services: Includes areas such as IT, finance, legal, and clinical coding. • Spend per agency EG- Total £10,000 Facilities £5,000 Admin £5,000 Agency x £5,000 facilities £5,000 Admin From January 2025 to 31st December 2025 please provide a breakdown month by month of total trust spend for off-framework agency staff within NON medical NON clinical, please break it down by: • Total spend • Spend per area EG – Admin and Clerical: Includes roles like receptionists, medical secretaries, ward clerks, administrators, and HR staff. Estates and Facilities: Encompasses porters, cleaners, caterers, maintenance workers, security staff, and drivers. Scientific, Therapeutic, and Technical Staff: A diverse group including various professions that do not fall under the direct 'medical' or 'nursing' umbrella. Corporate Services: Includes areas such as IT, finance, legal, and clinical coding. • Spend per agency EG- Total £10,000 Facilities £5,000 Admin £5,000 Agency x £5,000 facilities £5,000 Admin From January 2025 to 31st December 2025, please confirm which framework was used for the recruitment of agency staff within NON Medical NON clinical Please confirm whether the trust utilises a 3rd party vendor or tech system for the hiring of the NON Medical NON Clinical agency staff. If so, please confirm the name of the vendor / tech provider:

Date of Response: 29/01/2026
View Response: 11016.pdf

Freedom of Information Request Reference: 11014

Date Received: 08/01/2026

Summary:
I am writing to ask the following questions about individuals living with Functional Neurological Disorder (FND) in your Health Board area, which may also be recorded under the ICD-10 classification system as section F44 Dissociative and Conversion Disorders and the associated subsections. · Could you please respond as to how many individual persons of any age that are registered with a GP practice in your Health Board area as of 1st December 2025 that have been potentially or actually confirmed as having a diagnosis of Functional neurological disorder on their medical records either by naming the diagnosis as Functional neurological disorder, FND or recording under the ICD-10 classification of section F44 Dissociative and Conversion Disorders or categories thereunder (F44.4, F44.5, F44.6, F44.7 or F44.9). If you are trialling using the ICD-11 classification system at present I would be obliged if you used the appropriate coding classification. · Please indicate the number of individual persons that have been diagnosed or potentially diagnosed with FND or dissociative/conversion disorder by a neurologist in your Health Board area or by a specialist referral to another Board in the following tax years: 2020/2021 2021/2022 2022/2023 2023/2024

Date of Response: 30/01/2026
View Response: 11014.pdf

Freedom of Information Request Reference: 11013

Date Received: 07/01/2026

Summary:
I wish to make a Freedom of Information Request for the number of cancelled operations in 2020, 2021, 2022, 2023, 2024 & 2025.

Date of Response: 30/01/2026
View Response: 11013.pdf

Freedom of Information Request Reference: 11005

Date Received: 05/01/2026

Summary:
1. Where a child receives a private diagnosis of ADHD or a similar neurodevelopmental condition, does NHS Lothian recognise that diagnosis for the purposes of NHS prescribing? o Specifically, is the child or adult eligible for NHS prescriptions without requiring a repeat NHS assessment? 2. Does NHS Lothian have a formal policy regarding shared care arrangements following private diagnoses? o If so, please provide a copy. o If not, is any such policy currently under development? 3. Are GP practices within NHS Lothian required or encouraged to accept shared care agreements for children diagnosed privately? o If not, what guidance is provided to practices to support continuity of care? 4. Does NHS Lothian hold any information on which GP practices currently accept shared care arrangements for private ADHD diagnoses? o If such a list exists, please provide it. o If no list exists, what steps is the Board taking to improve transparency and communication for families seeking care? 5. What action is NHS Lothian taking to ensure that children with private diagnoses are not left without access to medication or monitoring, particularly in cases where their GP practice is unable to prescribe? 6. What policy advice has the Board received from the Scottish Government on this issue?

Date of Response: 10/02/2026
View Response: 11005.pdf

Freedom of Information Request Reference: 11000

Date Received: 05/01/2026

Summary:
I am writing to gather information regarding Adenomyosarcoma of the uterus: 1) How many procedures are performed for Adenomyosarcoma of the uterus annually in the gynaecology department within NHS Lothian? 2) What are the 5 Year survival outcomes?

Date of Response: 10/02/2026
View Response: 11000.pdf

Freedom of Information Request Reference: 10952

Date Received: 12/12/2025

Summary:
1.How many sexual safety incidents took place in trust premises since 1 Jan 2020 to date? 2.Please provide a breakdown of the total provided in question 1 by calendar year* (2020-to date) 3.Please provide a breakdown of the total provided in question 1 by type of sexual safety incident - e.g. a) rape, b) sexual assault etc 4.Please provide a breakdown of the total provided in question 1 by age of victim in the following categories: a) under 18, b) 18-64 and c) 65 and over** 5.Please provide a breakdown of the total provided in question 1 by status of the victim and perpetrator in the following categories: a. Perpetrator was a staff member and victim was staff member b. Perpetrator was a member of the public (or patient) and victim was a member of the public (or patient) c. Perpetrator was a member of the public (or patient) and victim was a staff member d. Perpetrator was a staff member and victim was a member of the public (or patient) 6.Please provide a breakdown of the total number of rapes since 1 Jan 2020 (i.e. the answer to 3.a) by the age of the rape victim in the following categories: a) under 18, b) 18-64 and c) 65 plus** 7. Does your trust have a dedicated policy to deal with sexual assault and harassment? If so please provide a copy of your trust’s written policy and if possible provide a date that the current policy was put in place.

Date of Response: 22/01/2026
View Response: 10952-1.pdf

Freedom of Information Request Reference: 10904

Date Received: 03/12/2025

Summary:
Under the FoI Act please provide the following information for Medical Staff by grade at the Royal Edinburgh Hospital Eden Ward Authorised and Actual levels by shift weekly for the period 1 February to 30 October 2025.

Date of Response: 06/02/2026
View Response: 10904.pdf

Freedom of Information Request Reference: 11011

Date Received: 07/01/2026

Summary:
What quantity of 10 % Dextrose with 0.15 % KCl was used in WGH during the last 6 months? ( I'd be happy for an answer relating to any defined period of more than a month and up to one year - whatever is easiest for you to answer. The timing of this could be anytime in the last two years). Same question for 10 % Dextrose on its own. Same question for any prepared infusions containing 0.15 % KCl.

Date of Response: 02/02/2026
View Response: 11011.pdf

Freedom of Information Request Reference: 11010

Date Received: 07/01/2026

Summary:
Question One: How many patients has your trust treated in the past six months (for any disease) with the following drugs: Aubagio (teriflunomide) Avonex (interferon beta-1a) Betaferon (interferon beta-1b) Brabio (glatiramer acetate) Copaxone (glatiramer acetate) Extavia (beta interferon-1b) Gilenya (fingolimod) Kesimpta (ofatumumab) Lemtrada (alemtuzumab) Mavenclad (cladribine) Mayzent (siponimod) Ocrevus (ocrelizumab) Plegridy (peginterferon beta-1a) Ponvory (ponesimod) Rebif (beta interferon-1a) Tecfidera (dimethyl fumarate) Tysabri (natalizumab) Tysabri (natalizumab) Pre-filled syringes only Vumerity (diroximel fumarate) Zeposia (ozanimod) Fingolimod generic Tyruko (Natalizumab Biosimilar) Briumvi (ublituximab) Question Two: How many patients has your trust treated with Rituximab for MS (Multiple Sclerosis) in the past six months? Question Three: How many patients within your trust have a diagnosis of MS (Multiple Sclerosis)?

Date of Response: 30/01/2026
View Response: 11010.pdf

Freedom of Information Request Reference: 11009

Date Received: 06/01/2026

Summary:
I would be grateful if you could provide copies of NHS Lothian’s current internal policies, procedures, guidance documents, or process maps relating to: 1.The internal process for referring a patient from one clinical department to another within NHS Lothian; and specifically 2. The internal process for referral to Ophthalmology; and 3. The internal process for referral to Neurosurgery within the Department of Clinical Neurosciences (or its current equivalent).

Date of Response: 03/02/2026
View Response: 11009.pdf

Freedom of Information Request Reference: 11008

Date Received: 06/01/2026

Summary:
I would like to request the following information for your healthcare trust during the period 1st Jan2015 to 31st December 2025: 1. Annual number of patients diagnosed with blood cancers per year overall, and by subtype: • Lymphomas (C81-86) • Malignant immunoproliferative diseases (C88) • Multiple myeloma and malignant plasma cell neoplasms (C90) • Leukaemia (C91-C95) • Unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues (C96) 2. The number of blood cancer clinical trials available, including active trials that are recruiting and trials that are not actively recruiting. 3. Annual number of patients who were enrolled in interventional or observational clinical trials related to these blood cancers per year. 4. The scientific title, clinical trial registration number, phase (I/II/III/IV/other), opening and closing recruitment dates, number recruited at this trust, and location of each trial related to blood cancer. 5. The current number of dedicated research staff (e.g. research nurses, research practitioners, study coordinators etc.) assigned to haematological clinical trials. 6. If available, annual counts of invitations/offers made to eligible patients to consider trial participation.

Date of Response: 03/02/2026
View Response: 11008.pdf

Freedom of Information Request Reference: 11007

Date Received: 06/01/2026

Summary:
I am writing to you under the Freedom of Information Act to request information on the following public sector contracts procured: 1. https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=NOV399947 Please can you let me know the following: • What is the total value of this contract? • What is the total length of the contract/or what is the expiry date?

Date of Response: 29/01/2026
View Response: 11007.pdf

Freedom of Information Request Reference: 11006

Date Received: 06/01/2026

Summary:
1) Has your organisation purchased implantable ports in the last 3 years? 2) If yes, to question 1, please can you kindly provide a purchasing export report detailing the following relevant to implantable ports for the time periods stated and name the files according to the financial year, including all supply routes. Time Periods ▪ 1st April 2022 – 31st March 2023 ▪ 1st April 2023 – 31st March 2024 ▪ 1st April 2024 – 31st March 2025 3) If yes, to question 1, please mark with an ‘x’ which clinicians/clinical areas implant ports: Surgeons Anaesthetists Interventional Radiology Vascular Access Nurses Other (Please State)

Date of Response: 28/01/2026
View Response: 11006.pdf

Freedom of Information Request Reference: 11003

Date Received: 06/01/2026

Summary:
In the period 1st October 2025 to 31st December 2025 please provide a breakdown of: • Total trust spend with framework agencies for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st October 2025 to 31st December 2025 please provide a breakdown of: • Total trust spend with off framework agencies for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st October 2025 to 31st December 2025 please provide a breakdown of: • Total trust spend with the internal trust bank or associated external provider for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name Please confirm the total number of nursing shifts booked during this period for all agency nursing only, no bank staff nursing to be included (1st October 2025 to 31st December 2025) Please confirm the total number of nursing shifts booked above NHSE capped rates during this period for all agency nursing only, no bank staff nursing to be included (1st October 2025 to 31st December 2025) Please confirm the framework you utilise for nursing agency staff.

Date of Response: 29/01/2026
View Response: 11003.pdf

Freedom of Information Request Reference: 11001

Date Received: 05/01/2026

Summary:
Number of shifts booked by ON Framework agency staff broken down by provider and month from January 2025 To December 31st 2025 Number of shifts booked by OFF Framework agency staff broken down by provider and month from January 2025 To December 31st 2025 Total spend on ON Framework agency staff broken down by agency and month from January 2025 To December 31st 2025 Total spend on OFF Framework agency staff broken down by agency and month from January 2025 To December 31st 2025

Date of Response: 29/01/2026
View Response: 11001.pdf

Freedom of Information Request Reference: 10999

Date Received: 05/01/2026

Summary:
Please provide the following information for December 2024 to November 2025, financial year 2024/25, or the most recent 12 month period available: 1. Scan volume Total number of lower limb duplex or Doppler ultrasound scans performed for suspected deep vein thrombosis (DVT). 2. Waiting times a) Average time from order to completion, or request to scan completion, whichever your systems record. b) If recorded, the number or percentage of patients who received their scan within: i. 4 hours ii. between 4 and 24 hours iii. between 24 and 48 hours iv. more than 48 hours after request (for example: X% within 4 hours, Y% between 4 and 24 hours, Z% more than 48 hours, etc). 3. Overnight admissions Number admitted overnight specifically to await their scan, if recorded.

Date of Response: 29/01/2026
View Response: 10999.pdf

Freedom of Information Request Reference: 10997

Date Received: 05/01/2026

Summary:
1) For the year 1st January 2025 - 31st December 2025 the total number of circumcisions performed for all age ranges at NHS Lothian. 2) For the year 1st January 2025 - 31st December 2025 the total number of circumcisions performed for all age ranges at NHS Lothian using general anaesthesia. 3) For the year 1st January 2025 - 31st December 2025 the total number of circumcisions performed for all age ranges at NHS Lothian using local anaesthesia. 4) For the year 1st January 2025 - 31st December 2025 the total number of circumcisions performed for therapeutic reasons for all age ranges using general anaesthesia at NHS Lothian. 5) For the year 1st January 2025 - 31st December 2025 the total number of circumcisions performed for therapeutic reasons for all age ranges using local anaesthesia at NHS Lothian. 6) For the year 1st January 2025 - 31st December 2025 the total number of circumcisions performed for religious and cultural using general anaesthesia at NHS Lothian. 7) For the year 1st January 2025 - 31st December 2025 the total number of circumcisions performed for religious and cultural reasons using local anaesthesia at NHS Lothian.

Date of Response: 29/01/2026
View Response: 10997.pdf

Freedom of Information Request Reference: 10994

Date Received: 05/01/2026

Summary:
1: Can you advise does the trust use plain or printed cable ties ?, even if you use them for other operations , if not would you consider starting to use them if a amicable budget can be found ? 2: What would be your annual usage ? 3: Can you advise the current price paid per thousand ?, if this is sensitive information please advise the price you would like to pay to fit your budget. 4: Advise the size of tie , colour and print required ?, we do offer a generic print or you can have department and wards to streamline waste better . 5: Name and email of the current waste manager 6: Address for samples if required . 7: Would bio degradable be of interest ? 8: who is your current supplier?, and are you under contract.

Date of Response: 29/01/2026
View Response: 10994.pdf

Freedom of Information Request Reference: 10991

Date Received: 31/12/2025

Summary:
I would be very grateful if you could provide the following information: 1. The name and role title of the current Clinical Lead (or equivalent senior clinical leadership role) for: - Ophthalmology - Diagnostic and Clinical Neurosciences (DCN) 2. The date from which each individual has held that role. 3. If applicable, the name of the previous Clinical Lead for each department and the date their term ended.

Date of Response: 29/01/2026
View Response: 10991.pdf

Freedom of Information Request Reference: 10990

Date Received: 30/12/2025

Summary:
Review request in relation to staff appraisal.

Date of Response: 27/01/2026
View Response: 10990.pdf

Freedom of Information Request Reference: 10989

Date Received: 31/12/2025

Summary:
1. Is Remifentanil PCA offered in all intrapartum settings in your health board, if not, which units is it offered? 2. Is Remifentanil PCA routinely available, offered on request, or available only under specific circumstances? 3. If possible, could you also provide any relevant clinical guidelines or criteria used to determine eligibility for remifentanil PCA in labour? 4. When these guidelines were introduced in your health board?

Date of Response: 02/02/2026
View Response: 10989.pdf

Freedom of Information Request Reference: 10978

Date Received: 22/12/2025

Summary:
For the years 2024 and 2025 how many 1. Locum consultants 2. Substantive consultants who were employed by the Trust, or through a locum agency, and were NOT on a specialist register.

Date of Response: 29/01/2026
View Response: 10978.pdf

Freedom of Information Request Reference: 10965

Date Received: 15/12/2025

Summary:
Copies of all protocols and guidelines used by the Chalmer Gender Identity Clinic for which WPATH SOC7 or WPATH SOC8 have been used as guidelines for the medical or surgical management of patients, including any shared care agreements with GPs.

Date of Response: 29/01/2026
View Response: 10965.pdf

Freedom of Information Request Reference: 10952

Date Received: 12/12/2025

Summary:
1.How many sexual safety incidents took place in trust premises since 1 Jan 2020 to date? 2.Please provide a breakdown of the total provided in question 1 by calendar year* (2020-to date) 3.Please provide a breakdown of the total provided in question 1 by type of sexual safety incident - e.g. a) rape, b) sexual assault etc 4.Please provide a breakdown of the total provided in question 1 by age of victim in the following categories: a) under 18, b) 18-64 and c) 65 and over** 5.Please provide a breakdown of the total provided in question 1 by status of the victim and perpetrator in the following categories: a. Perpetrator was a staff member and victim was staff member b. Perpetrator was a member of the public (or patient) and victim was a member of the public (or patient) c. Perpetrator was a member of the public (or patient) and victim was a staff member d. Perpetrator was a staff member and victim was a member of the public (or patient) 6.Please provide a breakdown of the total number of rapes since 1 Jan 2020 (i.e. the answer to 3.a) by the age of the rape victim in the following categories: a) under 18, b) 18-64 and c) 65 plus** 7. Does your trust have a dedicated policy to deal with sexual assault and harassment? If so please provide a copy of your trust’s written policy and if possible provide a date that the current policy was put in place.

Date of Response: 22/01/2026
View Response: 10952.pdf

Freedom of Information Request Reference: 10943

Date Received: 11/12/2025

Summary:
For each financial year from 2019/20 to 2025/26 (most recent): 1. the total number of referrals for a hysterectomy 2. the median completed wait (in days) for a hysterectomy 3. the longest completed waited (in days) for a hysterectomy 4. the median ongoing wait (in days) for a hysterectomy 5. the longest ongoing wait (in days) for a hysterectomy

Date of Response: 30/01/2026
View Response: 10943.pdf

Freedom of Information Request Reference: 10942

Date Received: 11/12/2025

Summary:
For each financial year from 2019/20 to 2025/26 (most recent): 1. The total number of laparoscopy procedures performed on women 2. The median completed wait (in days) for a laparoscopy procedure performed on women 3. The longest completed wait (in days) for a laparoscopy procedure performed on women 4. The median ongoing wait (in days) for a laparoscopy procedure performed on women 5. The longest ongoing wait (in days) for a laparoscopy procedures performed on women

Date of Response: 30/01/2026
View Response: 10942.pdf

Freedom of Information Request Reference: 10909

Date Received: 04/12/2025

Summary:
Please state the operational capacity and design capacity for the emergency departments of each of the hospitals listed below. • Royal Hospital for Children and Young People • Royal Infirmary of Edinburgh • St John’s Hospital For the hospitals listed, please confirm, the actual capacity of each one on the 1st of each month this year (January to December 2025).

Date of Response: 05/02/2026
View Response: 10909.pdf

Freedom of Information Request Reference: 10906

Date Received: 03/12/2025

Summary:
1. The number of taxi journeys paid for by the health board to transport patients to and from hospital appointments, including A&E, for each financial year from 2019-20 to 2024-25. 2. The total cost of taxi journeys paid for by the health board to transport patients to and from hospital appointments, including A&E, for each financial year from 2019-20 to 2024-25. 3. The furthest individual taxi journey recorded in each of those years (2019-20 to 2024-25), including the start and end locations (or distance if preferred).

Date of Response: 06/01/2026
View Response: 10906.pdf

Freedom of Information Request Reference: 10903

Date Received: 02/12/2025

Summary:
The number of women who received treatment for Female Genital Mutilation in each calendar year 2019, 2020, 2021, 2022, 2023, 2024 and 2025 to 30 June. The number of women who received deinfibulation surgery to treat Female Genital Mutilation in each calendar year 2019, 2020, 2021, 2022, 2023, 2024 and 2025 to 30 June.

Date of Response: 29/01/2026
View Response: 10903.pdf

Freedom of Information Request Reference: 10860

Date Received: 19/11/2025

Summary:
- How much have you spent on diversity / inclusion staff over the past five years, broken down into financial years. Please include this financial year to date: so data for 2019/20, 20/21, 22/23, 23/24, and 24/25 to date. - How much have you spent on diversity / inclusion training and materials over the past five years, broken down into financial years. Please include this financial year to date as above. - What external organisations have been paid to provide training and/or materials, and how much has been paid to each organisation over the years stated previously.

Date of Response: 30/01/2026
View Response: 10860.pdf

Freedom of Information Request Reference: 10827

Date Received: 06/11/2025

Summary:
1. Questions 1, 2 and 9. I will follow up with Data Protection team. Regarding Q9, it is simply not true that I was copied into all the emails. I know emails were exchanged between Kenny Scott and Craig Black in early July and I was not copied in. At this time I asked Kenny Scott to forward them to me but he declined. 2. . Question 3. This does not answer my question. I asked specifically and what checks and balances are in place, not whether there are checks and balances are in place. 'Ongoing monitoring' is not a satisfactory answer. What does this mean? What do they actually do? I have now spoken to others in my position and it appears the matter comes to light when they tell payroll and not because payroll unearthed the problem. Regarding eligibility and 2023. It is true SPPA rules changed at this time and some people became eligible to rejoin this particular scheme. However, NHS Lothian's legal duty to auto-enrol these people into an occupational scheme goes back many years before this. The change with the SPPA in 2023, I believe, served primarily as an external catalyst that unearthed people that had missed out for years. 3. Question 4. Perhaps this highlights the need to keep a central records to establish improved administration of the scheme to ensure NHS Lothian is compliant with their legal duties. 4. Question 5. I can do this. 5. Question 6. Does not answer the question have they made people aware. This is rather them being made aware by people affected by the failure to auto- enrol. 6. Questions 7&8. I have subsequently been made aware that it is the Finance Dept that are responsible for such matters so perhaps better these questions are addressed to them. I find it hard to believe there are no guideline/ policies regarding ex gratia and special payments generally if not specific to pensions. One example of such payments might be when an employee incurs bank charges due to a mistake in salary payments by Payroll. Such payments do exist and responsibility is taken in such matters.

Date of Response: 15/12/2025
View Response: 10827.pdf

Freedom of Information Request Reference: 11004

Date Received: 31/12/2025

Summary:
Please can you confirm the below for lung cancer screening programmes in your region/for the population you serve? • Is there a lung cancer screening programme in operation? If more than one, please state. • If applicable, who is the lead NHS organisation for this outside of the ICB/Cancer Alliance? • Is outsourced support from the Independent Sector used?

Date of Response: 22/01/2026
View Response: 11004.pdf

Freedom of Information Request Reference: 10998

Date Received: 05/01/2026

Summary:
Request in relation to medical record.

Date of Response: 05/01/2026
View Response: 10998.pdf

Freedom of Information Request Reference: 10996

Date Received: 05/01/2026

Summary:
How much money over the last 10 years, broken down by year, has your health board given to Stonewall. Please also include the reasons for the payment.

Date of Response: 26/01/2026
View Response: 10996.pdf

Freedom of Information Request Reference: 10993

Date Received: 05/01/2026

Summary:
Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: •Adalimumab - Humira •Adalimumab Biosimilar •Apremilast •Bimekizumab •Brodalumab •Certolizumab •Deucravacitinib •Dimethyl fumarate •Etanercept - Enbrel •Etanercept Biosimilar •Guselkumab •Infliximab - Remicade •nfliximab Biosimilar •Ixekizumab •Risankizumab •Secukinumab •Tildrakizumab •Ustekinumab - Stelara •Ustekinumab Biosimilar •Omalizumab •Spesolimab Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following: •Adalimumab - Humira •Adalimumab Biosimilar •Bimekizumab •Certolizumab •Infliximab - Remicade •Infliximab Biosimilar •Secukinumab •Ustekinumab - Stelara •Ustekinumab Biosimilar

Date of Response: 26/01/2026
View Response: 10993.pdf

Freedom of Information Request Reference: 10992

Date Received: 05/01/2026

Summary:
Could you please let me know which active primary care rebate schemes your organisation are currently signed up to? Could you please provide the start and end dates of the contracts?

Date of Response: 27/01/2026
View Response: 10992.pdf

Freedom of Information Request Reference: 10988

Date Received: 30/12/2025

Summary:
If, in January 2023, a consultant orthopedic surgeon employed by NHS Lothian was to access x-ray images taken within NHS Tayside in September 2018 - what would be the correct protocol and procedure for doing so? Would any such access to the Picture Archiving and Communication System (PACS) be logged within the NHS Tayside and/or NHS Lothian systems.

Date of Response: 23/01/2026
View Response: 10988.pdf

Freedom of Information Request Reference: 10984

Date Received: 29/12/2025

Summary:
Please could you confirm the below details for all CT and MRI scanners owned by the Trust? Site (location) Modality EOM and scanner model Year of manufacture Designated for

Date of Response: 22/01/2026
View Response: 10984.pdf

Freedom of Information Request Reference: 10983

Date Received: 29/12/2025

Summary:
1.) Please provide the name of NHS Lothian’s organisational process that states that any communication from a patient that allegedly intimates a complaint is to be logged with the Patient Experience Team and that this process does not require the patient’s consent for their data to be passed to the complaints team. 2.) please provide a copy of this process 3.) please provide the date this process was put in place 4.) please explain how this process is communicated to all nhs Lothian staff 5.) please explain how it is made sure that this process is not exploited by staff to the detriment of the patient 6.) please advise where this process is available for patients to view and how they are informed about it 7.) please advise why patients’ consent is not sought for nhs Lothian using their data to submit a complaint on their behalf under this process 8.) please advise what happens to communication addressed to the chief executive of nhs Lothian that was first miscategorised as a complaint by nhs Lothian staff and then was referred back to the chief executive of nhs Lothian for a response. What is considered to be a reasonable time for the chief executive of nhs Lothian to respond to an urgent matter referred to her? 9.) please advise what percentage of those complaint cases that were submitted between 01/06/25 - 24/12/25 to nhs Lothian complaints team suffered a delay in the investigation process and on average how long this delay was.

Date of Response: 26/01/2026
View Response: 10983.pdf

Freedom of Information Request Reference: 10982

Date Received: 29/12/2025

Summary:
1. The number of staff currently recorded by the organisation as belonging to the Armed Forces Community. This includes reservists, veterans, service leavers, cadet force adult volunteers, and staff who have identified as spouses or dependants of serving personnel. 2. The number of staff who have registered with the organisation's Armed Forces Community contact in each of the last three financial years. 3. Any monitoring information, summaries or internal documents produced in the last three financial years that record uptake of Armed Forces related support within the organisation. This includes reservist training leave, Armed Forces related flexible working, or any other support schemes aimed at the Armed Forces Community.

Date of Response: 22/01/2026
View Response: 10982.pdf

Freedom of Information Request Reference: 10981

Date Received: 23/12/2025

Summary:
Could you confirm, in the number of months, the remaining waiting time for adult ADHD assessment in East Lothian, for patients referred for assessment in July 2023, please?

Date of Response: 20/01/2026
View Response: 10981.pdf

Freedom of Information Request Reference: 10980

Date Received: 22/12/2025

Summary:
1. Does your Trust hold a record or inventory of medical-grade freezer units used for the storage of biological, histopathology, research, or biobanking tissue samples? a. If yes, please provide the (a) number of units and (b) storage temperature category (for example -20°C, -80°C) 2. Are any of these freezer units currently used for the rapid freezing and/or long-term storage of brain tissue samples? a. If yes, please state (a) the number of units used for brain tissue and (b) the typical storage temperature used. 3. Regardless of current use, does the Trust have freezer units capable of supporting fresh- or flash- frozen brain tissue storage that is suitable for therapeutic development. a. Does the Trust currently have access to rapid freezing equipment suitable for brain tissue? 4. Only if feasible within the FOI time and cost limit, please indicate whether any existing freezer unit in the Trust could be repurposed or shared between departments to enable brain tissue storage or expand current capacity.

Date of Response: 23/01/2026
View Response: 10980.pdf

Freedom of Information Request Reference: 10979

Date Received: 22/12/2025

Summary:
I am making a request for information under the Freedom of Information (Scotland) Act 2002 in relation to NHS Lothian’s handling and investigation of complaint reference ~~~~~, received on ~~~~~ 2025. This request concerns governance, process, and documentary records relating to the investigation and complaint handling. It does not seek personal medical records. Please provide the following information: 1. Investigation and Decision-Making Roles The professional roles and job titles of individuals involved in: • investigating complaint ~~~~~, • drafting the response issued on ~~~~~ 2025, • drafting the subsequent response issued following the reopening of the complaint, • reviewing, approving, or signing off each response. 2. Staff Accounts Considered Confirmation of which staff members’ accounts were obtained or relied upon during the investigation, including whether accounts were sought from: • the ~~~~~ who was the subject of the complaint, • the ~~~~~ who received the clinical handover, • any other clinical staff involved in the episode of care. 3. Evidence Reviewed A list of the categories of evidence reviewed during the investigation, including: • clinical records, • written patient documentation, • staff accounts, • relevant policies or guidelines. Please confirm whether the written ~~~~~ provided by the complainants was reviewed as part of the investigation. 4. Internal Correspondence Copies of internal correspondence created between ~~~~~ 2025 and the date of the most recent response relating to: • the investigation of complaint ~~~~~, • management of response timescales, • decisions to extend the Stage 2 response timeframe, • the decision to reopen the complaint, • preparation and issue of the further response following reopening. 5. Governance, Risk, or Legal Involvement Confirmation of whether NHS Lothian’s governance, risk, or legal teams were consulted in relation to complaint ~~~~~, including: • the stage or stages at which consultation occurred, • the purpose of that consultation. 6. Timescale Management Records documenting decisions to extend the Stage 2 complaint response timescale beyond 20 working days, including: • dates on which extensions were agreed, • reasons recorded for those extensions. 7. Complaint Handling Guidance Copies of the complaint-handling procedures, guidance, or flowcharts relied upon when managing complaint ~~~~~, including those relating to reopened complaints.

Date of Response: 23/01/2026
View Response: 10979.pdf

Freedom of Information Request Reference: 10974

Date Received: 22/12/2025

Summary:
Under the FOI legislation I would like copies of the CMT team - and management reports iMatter score and action plans for last five years including the most recent one.

Date of Response: 26/01/2026
View Response: 10974.pdf

Freedom of Information Request Reference: 10970

Date Received: 17/12/2025

Summary:
I am looking to verify Contract Start and End Dates to understand framework adherence and competition in the workforce management sector. I am not requesting financial/spend data. Please provide the Provider Name, Contract Start Date, and Contract End Date for the systems listed below. Group 1: Workforce Scheduling • E-Rostering (Medics) • E-Rostering (AHP) • E-Rostering (Nurses) • Bank Technology Platform (Medics) • Bank Management System (Medics) (if not in-house) Group 2: Workforce Planning & Review • Job Planning System (Medics) • Appraisals (Medics) • Multi-Source Feedback (MSF) System (Medics)

Date of Response: 23/01/2026
View Response: 10970.pdf

Freedom of Information Request Reference: 10960

Date Received: 16/12/2025

Summary:
Under the Freedom of Information Act 2000, please provide the following information: 1. For the period 1 January 2024 to 31 December 2024, and separately 1 January 2025 to 31 December 2025 (or, if more readily available, FY 2023/24 and FY 2024/25): • The total number of Plain Radiography (X-ray / plain film) examinations performed by the Trust. 2. For the same period(s), please provide: • The total number of examinations reported externally (outsourced / via teleradiology), broken down by modality where available: o Plain film (X-ray) o CT o MRI o Ultrasound o Other (please specify) • The total expenditure (£) on outsourced radiology reporting services, broken down by supplier. • The names of the suppliers used for outsourced reporting (for example, Everlight, Medica, etc.) and the total amount paid to each supplier. 3. Where available, please include any internal categorisation used by the Trust (for example, urgent vs routine reporting, out-of-hours reporting, or turnaround time bands).

Date of Response: 23/01/2026
View Response: 10960.pdf

Freedom of Information Request Reference: 10941

Date Received: 11/12/2025

Summary:
1. Please provide the total number of advanced practitioners employed in your Trust/Board for each of the years 2021 to 2025. If possible, please break this information down by department or specialty. 2. a)Please could you provide the salary range for advanced practitioners employed in your Trust/Board for each of the years 2021 to 2025. b) Please could you provide the total salary expenditure for advanced practitioners employed in your Trust/Board for each of the years 2021 to 2025. 3. Please could you provide the total number of hours worked by advanced practitioners employed in your Trust/Board for each of the years 2021 to 2025. 4. a) Please could you provide us with any existing documentation which describes the job duties and responsibilities of advanced practitioners within your Trust/Board. b) If not covered in existing documentation, please confirm whether in your Trust/Board advanced practitioners ever i) make referrals to other specialties ii) hold crash / emergency bleeps 5. Within your Trust/Board, please could you tell us a) if advanced practitioners are ever deployed on medical rotas b) if advanced practitioners are permitted to cover doctor rota gaps c) what grade of doctors advanced practitioners are permitted to cover for d) if merged/tiered/general rotas with mixed staffing groups are used and if so, which types and grades of clinicians appear on these rotas. 6. a) Please provide us with a copy of bank shift rotas currently used for all medical and non-medical roles within your Trust/Board b) Please provide us with the current hourly rate-range paid to advanced practitioners working bank shifts in your Trust/Board, broken down by years of service if applicable.

Date of Response: 26/01/2026
View Response: 10941.pdf

Freedom of Information Request Reference: 10939

Date Received: 11/12/2025

Summary:
Q1. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the total number of patients who received care or clinical attention in corridors or other non-designated clinical areas. Please breakdown by financial year if possible. Q2. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the total number the total number of hours patients collectively spent receiving corridor care. Please breakdown by financial year if possible. Q3. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the longest individual recorded duration a patient spent receiving care in a corridor or non-designated area during each year. Please breakdown by financial year if possible. Q4. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide copies of any risk assessments, safety reviews, or incident reports specifically relating to the use of corridor care. Please breakdown by financial year if possible. Q5. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the total number of patients who presented with Catheter-Associated Urinary Tract Infections (CAUTIs) whilst in your care. Please breakdown by financial year if possible. Q6. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the total number of patients who presented with Surgical Site Infections (SSIs) whilst in your care. Please breakdown by financial year if possible. Q7. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the total number of patients who presented with Central Line-Associated Bloodstream Infections (CLABSIs) whilst in your care. Please breakdown by financial year if possible. Q8. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the total number of patients who presented with Clostridioides difficile (C. diff) Infections) whilst in your care. Please breakdown by financial year if possible. Q9. In the financial years 2020 - 2021, 2021 - 2022, 2022 - 2023, 2023 - 2024, 2024 - 2025, please provide the total number of patients who presented with Methicillin-Resistant Staphylococcus aureus (MRSA) whilst in your care. Please breakdown by financial year if possible.

Date of Response: 23/01/2026
View Response: 10939.pdf

Freedom of Information Request Reference: 10929

Date Received: 09/12/2025

Summary:
Please note, that my questions are in relation to fellowships in Trauma and Orthopaedics only. 1. Do you currently offer, or have you offered in the last year any post CCT (or equivalent) fellowships in trauma and orthopaedics? 2. For each fellowship that you offer, please could you answer/provide the following; a. What is the sub-speciality? b. What was the advertised base pay (or nodal point e.g. MT04, MT05) that the job offers? c. Does the fellowship include being part of an on-call rota, or attract any uplift from the base pay? d. Is that inclusion on the on-call rota optional? e. If yes to question c, please include a copy of the rota, and associated uplift in pay? f. How many annual leave days does this fellowship allow? g. How many study leave days does this fellowship allow? h. What is the study leave budget for the fellowship? i. Please include a copy of the job description and person specification for the job

Date of Response: 27/01/2026
View Response: 10929.pdf

Freedom of Information Request Reference: 10920

Date Received: 09/12/2025

Summary:
Provider 1 1. What is the name of your Admin and Clerical Collaborative Bank software provider? (None if software not used) 2. When did the contract for this provider start? (dd/mm/yyyy) (None if software not used) 3. When does the contract for this provider expire? (dd/mm/yyyy) (None if software not used) Provider 2 (If applicable) 4. What is the name of your second Admin and Clerical Collaborative Bank software provider? (If you have more than one provider) 5. When did the contract for this second provider start? (dd/mm/yyyy) 6. When does the contract for this second provider expire? (dd/mm/yyyy) Provider 3 (If applicable) 7. What is the name of your third Admin and Clerical Collaborative Bank software provider? (If you have more than one provider) 8. When did the contract for this third provider start? (dd/mm/yyyy) 9. When does the contract for this third provider expire? (dd/mm/yyyy) Additional 10. What was the Trust's total spend on Admin and Clerical Collaborative Bank fees in 2024 (excluding implementation)? 11. What was the Trust's total spend on Admin and Clerical Collaborative Bank fees in 2025 (excluding implementation)?

Date of Response: 23/01/2026
View Response: 10920.pdf

Freedom of Information Request Reference: 10760

Date Received: 29/10/2025

Summary:
1. The number of babies born at Simpsons (Edinburgh Royal Infirmary) from 1st October 2024 to 1st October 2025. 2. How many of the babies born in Question 1 were born at less than 27 weeks gestation, or weighed less than 800 grams, or needed multiple intensive care interventions or surgeries.

Date of Response: 27/01/2026
View Response: 10760.pdf

Freedom of Information Request Reference: 10751

Date Received: 28/10/2025

Summary:
1. Among all the children and young people from your health board area who waited in excess of the 18- week CAMHS standard and started their treatment in (a) 2024/25 and b) 2025/26 to date (including those still waiting), what was the total number of days over the 18-week standard that they collectively waited. Please break down the figures for each year specified. For example, if a child began their treatment after 30 weeks, then that child would contribute 84 days towards the total for the year in which they started their treatment (12 weeks x 7 days).

Date of Response: 27/01/2026
View Response: 10751.pdf

Freedom of Information Request Reference: 10973

Date Received: 19/12/2025

Summary:
I would like to submit an FOI request for the number of vials used and patients treated for the following products (see table below) at your trust used in 2025 (total January to December), broken down by brand and size, if possible. If the full-year data is not yet available, you can inform me about the currently available data. Prothrombin Complex Concentrate (PCC) Beriplex Octaplex Prothromplex FEIBA Others (if any please specify) Reversal Agents Ondexxya (andexanet alfa) Praxbind (Idaracizumab) Fibrinogen Concentrate (FC) RiaSTAP FibCLOT Fibryga Others (if any please specify) Fresh Frozen Plasma (FFP) Fresh Frozen Plasma Octaplas Cryoprecipitate Cryoprecipitate Labile Blood Products Whole blood Red blood cells Platelets Factor XIII Fibrogammin

Date of Response: 20/01/2026
View Response: 10973.pdf

Freedom of Information Request Reference: 10972

Date Received: 17/12/2025

Summary:
1.) The number of patients NHS Lothian Primary Care assigned to Annandale Medical Practice, 26 Huntingdon Place, Edinburgh, EH7 4AT in 2025 (01/01/25 - 17/12/25) from out of catchment area. 2.) The number of patients NHS Lothian Primary Care assigned to Annandale Medical Practice, 26 Huntingdon Place, Edinburgh, EH7 4AT in 2024 from out of catchment area. 3.) Is Annandale Medical Practice, 26 Huntingdon Place, Edinburgh, EH7 4AT on NHS Lothian Primary Care's GP practice list that NHS Lothian Primary Care use when NHS Lothian Primary Care assign patients to GP practices from out of catchment area?

Date of Response: 20/01/2026
View Response: 10972.pdf

Freedom of Information Request Reference: 10969

Date Received: 17/12/2025

Summary:
Please answer the following two questions giving numbers for each of the following financial years (i) 2020/21, (ii) 2021/22, (iii) 2022/23, (iv) 2023/24 and (v) 2024/25 1. How many people were (a) treated by your trust where the external cause of them being admitted was recorded as X31 Exposure to excessive natural cold. 2. Of the people referred to in Question 1 how many of them were logged where any of their diagnosis codes (either primary diagnosis or a secondary diagnosis) were (a) any form of pneumonia, or (b) T68 X hypothermia.

Date of Response: 20/01/2026
View Response: 10969.pdf

Freedom of Information Request Reference: 10968

Date Received: 17/12/2025

Summary:
Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which. Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following: •Belantamab Mafodotin [Blenrep] •Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone •Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone •Bortezomib [Velcade] ± Dexamethasone •Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) •Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) •Carfilzomib [Kyprolis] + Dexamethasone •Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) •Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) •Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) •Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) •Daratumumab [Darzalex] monotherapy •Elranatamab •Idecabtagene vicleucel [Abecma] •Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) •Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) •Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) •Lenalidomide [Revlimid] + Dexamethasone •Lenalidomide [Revlimid] monotherapy •Panobinostat + Bortezomib + Dexamethasone •Pomalidomide [Imnovid] + Dexamethasone •Selinexor + Bortezomib [Velcade] + Dexamethasone •Selinexor + Dexamethasone •Talquetamab •Teclistamab [Tecvayli] •Any other systemic anti-cancer therapy [please specify] Q3. In the last 6 months, how many patients have been initiated* on the following regimens? •Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) •Carfilzomib [Kyprolis] + Dexamethasone •Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) •Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) •Daratumumab [Darzalex] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Dara-VRd) •Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) •Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) •Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) •Lenalidomide [Revlimid] monotherapy •Lenalidomide [Revlimid] + Dexamethasone •Selinexor + Bortezomib [Velcade] + Dexamethasone •Selinexor + Dexamethasone •Any other systemic anti-cancer therapy [please specify] *Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) during the calendar year 2025 prior to initiation. Q4. In the last 6 months, how many patients have received the following second-line treatment? •Lenalidomide [Revlimid] + Dexamethasone

Date of Response: 20/01/2026
View Response: 10968.pdf

Freedom of Information Request Reference: 10967

Date Received: 17/12/2025

Summary:
1. Do Staff Rest Areas / Break Rooms across NHS Lothian have televisions for staff to utilise whilst on a rest period? 2. Are these TVs required to be covered by a TV Licence? 3. If yes to question number 2, how are these licences paid for? (a) Paid for centrally, by NHS Scotland. (b) Paid for by NHS Lothian. (c) Paid for by the staff who use the break rooms (Such staff Tea Funds, Social Funds etc that are contributed to by individual staff) (d) Other - Please Specify.

Date of Response: 20/01/2026
View Response: 10967.pdf

Freedom of Information Request Reference: 10966

Date Received: 17/12/2025

Summary:
Please can you break down for calendar years 2019, 2020, 2021, 2022, 2023, 2024 and 2025 (up to present date): a) The number of children waiting for the start of treatment via CAHMS b) The longest wait for children starting treatment via CAHMS c) The average wait for children starting treatment via CAHMS

Date of Response: 20/01/2026
View Response: 10966.pdf

Freedom of Information Request Reference: 10964

Date Received: 17/12/2025

Summary:
Regarding the procurement and usage of surgical swabs within your hospital theatres. Specifically, I would like to request the following information: 1. Current Supplier and Contract Details •Who is the current supplier of surgical swabs used in theatre? •What is the scope of the contract (e.g., product types, volumes, duration)? 2. Usage and Procurement •Approximate annual usage volume of surgical swabs in theatre. •List by product group qty, dimension, Qty, Hospital and company provider. •Any guidelines on who should be contacted within procurement 3. Contract Renewal •When is the current contract for surgical swabs due for renewal? •Will the contract be subject to re-tendering, extension, or automatic renewal? 4. Future Planning •Are there any planned changes to procurement strategy for surgical swabs (e.g., moving to framework agreements, sustainability initiatives, or alternative suppliers)?

Date of Response: 20/01/2026
View Response: 10964.pdf

Freedom of Information Request Reference: 10963

Date Received: 17/12/2025

Summary:
How many of completed SAER's have the outcome code Appropriate care, how many is the outcome code indirect system of care issues?

Date of Response: 19/01/2026
View Response: 10963.pdf

Freedom of Information Request Reference: 10962

Date Received: 16/12/2025

Summary:
Q1. Does your health board place a restriction upon the number of dialysis away from base (DAFB) sessions it will cover the cost of within a calendar year within the UK ? If YES: If there are any restrictions in place, please list what these are.

Date of Response: 19/01/2026
View Response: 10962.pdf

Freedom of Information Request Reference: 10961

Date Received: 16/12/2025

Summary:
Please can you provide the following: A) Any documentation that sets of the Health Boards policy in meeting its commitments with the Armed Forces Covenant. B) Confirmation whether the Health Board has a Veterans Network to help veterans seeking access to services. C) For the last five financial years, 2024/25, 2023/24, 2022/23, 2021/22, 2020/21, please provide the cost, if any, of providing services as part of the Health Boards commitment with the Armed Forces Covenant.

Date of Response: 19/01/2026
View Response: 10961.pdf

Freedom of Information Request Reference: 10958

Date Received: 16/12/2025

Summary:
1. The average waiting times for category 5 CT scans between April 2021 to September 2021 for inpatients at Western General Hospital, Crewe Road South, Edinburgh and Royal Infirmary of Edinburgh, 51 Little France Crescent, Old Dalkeith Road, Edinburgh. 2. The average waiting times for CT scans undertaken where there is a suspected bowel perforation for inpatients at Western General Hospital, Crewe Road South, Edinburgh and Royal Infirmary of Edinburgh, 51 Little France Crescent, Old Dalkeith Road, Edinburgh.

Date of Response: 08/01/2026
View Response: 10958.pdf

Freedom of Information Request Reference: 10957

Date Received: 15/12/2025

Summary:
I would please like to know, in each of the last three years for which you have data: 1) The number of staff employed by the trust 2) The total number of days of sick leave taken by staff who took paternity leave in the preceding 12 months 3) The total number of days of sick leave taken by all staff across the trust

Date of Response: 12/01/2026
View Response: 10957.pdf

Freedom of Information Request Reference: 10956

Date Received: 15/12/2025

Summary:
I would be grateful if you could please provide a copy of the Joint Working Arrangements between NHS Lothian and West Lothian Council to ensure that the Integration Joint Board (IJB) is undertaken in accordance with the Public Bodies (Joint Working) (Scotland) Act 2014 and related orders.

Date of Response: 12/01/2026
View Response: 10956.pdf